title: Induction of cytotoxic T cell response against HCA661 positive cancer cells through activation with novel HLA-A *0201 restricted epitopes.
abstract: HCA661 is a cancer-testis (CT) antigen frequently expressed in human hepatocellular carcinoma (HCC). To search for immunogenic peptides of HCA661, bioinformatics analysis and CD8(+) T cell IFN-gamma ELISPOT assay were employed, and two HLA-A *0201 restricted peptides, H110 and H246, were identified. These two HCA661 peptides are naturally processed in dendritic cells (DCs) and when used for DCs loading, they are sufficient to prime autologous CD8(+) T cells to elicit cytotoxic response against HCA661(+) human cancer cells. The HCA661 peptides, H110 and H246, are hence attractive candidates for human cancer immunotherapy.
authors.affiliation: Department of Biology, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China.
authors.forename: Paul Ha-Sang
authors.initials: PH
authors.lastname: Pang
authors.forename: Kin-Tak
authors.initials: KT
authors.lastname: Chan
authors.forename: Luigi Ying-Wai
authors.initials: LY
authors.lastname: Tse
authors.forename: Ray Chun-Fai
authors.initials: RC
authors.lastname: Chan
authors.forename: Ying-Kit
authors.initials: YK
authors.lastname: Cheung
authors.forename: Fion Wan-Yee
authors.initials: FW
authors.lastname: Sin
authors.forename: Zhi-Hong
authors.initials: ZH
authors.lastname: Guo
authors.forename: Yong
authors.initials: Y
authors.lastname: Xie
mesh_terms: D015703:Antigens, CD / Q000276:immunology*; D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D015816:Cell Adhesion Molecules, Neuronal / Q000276:immunology*; D045744:Cell Line, Tumor; D002470:Cell Survival; D019295:Computational Biology; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping / Q000379:methods; D005240:Feasibility Studies; D005326:Fetal Proteins / Q000276:immunology*; D015234:HLA-A Antigens / Q000276:immunology*; D015789:HLA-A2 Antigen; D006801:Humans; D016056:Immunodominant Epitopes; D007167:Immunotherapy / Q000379:methods; D007371:Interferon-gamma / Q000378:metabolism; D008113:Liver Neoplasms / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism; D020410:Activated-Leukocyte Cell Adhesion Molecule
chemical_list: D015703:Antigens, CD; D015816:Cell Adhesion Molecules, Neuronal; D005326:Fetal Proteins; D015234:HLA-A Antigens; D015789:HLA-A2 Antigen; D016056:Immunodominant Epitopes; D007371:Interferon-gamma; C105613:ALCAM protein, human; D020410:Activated-Leukocyte Cell Adhesion Molecule; C435939:HLA-A*02:01 antigen